FINWIRES · TerminalLIVE
FINWIRES

HKG:2196

32 stories mentioning HKG:2196Updated just now

Every FINWIRES story that references HKG:2196, newest first.

What's the latest news on HKG:2196?

Asia

Chinese Drug Regulator Accepts Fosun Pharma's Application for HLX14; Shares Up 5%

China's National Medical Products Administration accepted Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) application for the 120 milligram per vial of HLX14, or recombinant anti-RANKL fully human monoclonal antibody injection, according to a Shanghai bourse filing on the weekend.The pharmaceutical company's Hong Kong shares jumped 5%, while Shanghai shares rose 2% during Monday's midday trade.Fosun's subsidiary, Shanghai Henlius Biotech, developed the drug, which has been approved for marketing in the U.S., the European Union, the U.K. and Canada.

HKG:2196SHA:600196
Asia

Fosun Pharma Gets China Approval for Phase 2/3 Vitiligo Drug Trial

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said a subsidiary received approval in China for the phase 2/3 adaptive seamless-design clinical trial of FXS5626 for non-segmental vitiligo.Following the National Medical Products Administration's clearance, Shanghai Fosun Pharmaceutical Industrial Development plans to start the trial in mainland China when conditions are met, according to a Tuesday Hong Kong bourse filing.Fosun Pharma has invested 108 million yuan in FXS5626 research and development as of August, including license fees.

HKG:2196SHA:600196
Asia

Fosun Pharmaceutical Extends Deadline of 81 Million Yuan Shareholder Loans to Fuyun Health; Shares Up 7%

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196), along with its controlling shareholder and subsidiaries, agreed to extend the shareholder loans worth 80.8 million yuan provided to Fuyun Health for another year, according to a Shanghai bourse filing over the weekend.The Chinese pharmaceutical company's Hong Kong shares jumped 7%, while Shanghai shares rose 1% during Monday's midday trade.The loans' extended maturity date will be Sept. 4, 2027, and the annual interest rate during the extension period will remain at 3.2%.

HKG:2196SHA:600196
Fosun Pharma Plans HK$1 Billion Share Buyback Funded by Gland Pharma Stake Sale
US Markets

Fosun Pharma Plans HK$1 Billion Share Buyback Funded by Gland Pharma Stake Sale

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) plans to repurchase up to HK$1 billion of its H-shares over a 12-month period.The plan, which the Chinese pharmaceutical firm said was designed to address market concerns and bolster shareholder value, will be funded by a divestment in its Indian unit.Fosun's indirect subsidiary, Fosun Pharma Singapore, sold 9.897 million shares in Gland Pharma (NSE:GLAND, BOM:543245) for about 28 billion Indian rupees. The sale was executed through block trades and open-market transactions at an average price of 2,828.78 rupees each, representing a 2.72% discount to the previous close.The sale reduces Fosun International's equity stake in Gland Pharma to 45.76% from 51.76%. Gland Pharma will remain a subsidiary of Fosun Pharma and its financial results will continue to be consolidated under Fosun's umbrella.The share buyback follows an upbeat first half for Fosun Pharma. Attributable net profit jumped 19.1% year over year to 1.14 billion yuan on the back of a 4.75% increase in revenue to 20.4 billion yuan."Looking ahead, Fosun Pharma will stay focused on innovation and globalization, accelerating the R&D progress and commercialization of its major pipeline candidates," the company said.Fosun Pharma's shares jumped more than 7% in Hong Kong and over 1% in Shanghai in recent trade.

BOM:543245HKG:2196NSE:GLANDSHA:600196
Asia

Fosun International Unit Sells 6% Gland Pharma Stake for INR28 Billion

Fosun International (HKG:0656) said its indirect subsidiary Fosun Pharma Singapore sold 9.897 million shares in India's Gland Pharma (NSE:GLAND, BOM:543245) for about 28 billion rupees through block trades and open-market transactions.The sale cuts Fosun International's stake in Gland Pharma to 45.76% from 51.76%, according to a Sunday Hong Kong bourse filing.Gland Pharma will remain a subsidiary of Fosun Pharma (HKG:2196, SHA:600196), with its results continuing to be consolidated.Shanghai Fosun Pharmaceutical plans to repurchase up to HK$1 billion of its H-shares, with the buyback mainly funded by proceeds from the sale of its Gland Pharma stake.The shares were sold at an average price of about 2,828.78 rupees each, including transaction costs, a 2.72% discount to Gland Pharma's previous close.Proceeds will be used mainly for research and development, share repurchases, and repayment of interest-bearing borrowings.

BOM:543245HKG:0656HKG:2196NSE:GLANDSHA:600196
Asia

Fosun Pharma Plans Up to HK$1 Billion H-Share Buyback

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) plans to repurchase its H-shares worth up to HK$1 billion, according to a press release on Sunday.The repurchased shares will either be cancelled or held as treasury shares.The buyback will be mainly funded by proceeds from the $294 million sale of a roughly 6% stake in India's Gland Pharma (NSE:GLAND, BOM:543245). Fosun Pharma retained a 45.8% stake in Gland Pharma following the divestment.

BOM:543245HKG:2196NSE:GLANDSHA:600196
Asia

Fosun Pharma Gets China Approval for Luvometinib in Adults With Nerve Tumors

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said China's National Medical Products Administration approved an additional indication for its Luvometinib tablets.The approval covers adults with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that cannot be completely removed.The drug was previously approved in China for three other indications, including treatment of pediatric NF1 patients with symptomatic plexiform neurofibromas.

HKG:2196SHA:600196
Asia

Regent Pacific Gets $4.5 Million Milestone Payment from Fosun Pharma Unit

Regent Pacific (HKG:0575) received a milestone payment of $4.5 million from Fosun Wanbang (Jiangsu) Pharmaceutical Group on Monday.The payment was received under a licence and collaboration arrangement related to Senstend between the parties, according to a Tuesday bourse filing.Fosun Wanbang (Jiangsu) Pharmaceutical Group is expected to begin the commercialization of Senstend in China, leading to further milestone and royalty payments to the company.Fosun Wanbang (Jiangsu) Pharmaceutical Group is a unit of Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196).

HKG:0575HKG:2196SHA:600196
Asia

Shanghai Fosun Pharmaceutical's GR1803 Injection Gets Conditional Approval in China

Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) GR1803 injection received conditional approval from China's National Medical Products Administration as a multiple myeloma treatment, according to a Friday disclosure on the Shanghai bourse.The drug, which has the generic name veritumab injection, is for adult patients with relapsed or refractory multiple myeloma who have previously received at least three lines of therapy, including a proteasome inhibitor and an anti-CD38 monoclonal antibody.

HKG:2196SHA:600196
Asia

Fosun Pharma Posts Flat Profit Growth in H1, Revenue Up 4.8%

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) reported an attributable net profit of 1.72 billion yuan for the first half, up 1.15% from 1.70 billion yuan a year earlier.Earnings per share stood at 0.65 yuan, inching up from 0.64 yuan in the year-ago period, according to a Tuesday filing with the Hong Kong bourse.Revenue increased 4.75% year over year to 20.4 billion yuan from 19.4 billion yuan.

HKG:2196SHA:600196
Asia

Fosun Pharma Starts Phase Two Trial for COPD Drug

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) controlled unit Fosun Pharma Industry started the Phase Two clinical trial in China for FXS7553, targeting chronic obstructive pulmonary disease (COPD), according to a Thursday aftermarket filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade on the Shanghai and Hong Kong bourses.

HKG:2196SHA:600196
Asia

Fosun Pharma Secures China Approval for Two Drugs

China's National Medical Products Administration (NMPA) has accepeted two drug registration applications by subsidiaries of Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196), according to separate disclosures filed with the Hong Kong Exchange on Friday.The approvals cover Levosalbutamol Hydrochloride Nebuliser Solution, developed by Fosun Pharma (Xuzhou), and Dobutamine Hydrochloride Injection, developed by Shanghai Zhaohui Pharmaceutical Company.Levosalbutamol Hydrochloride Nebuliser Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children aged six years and older with reversible obstructive airway disease.Dobutamine Hydrochloride Injection is approved for the short-term supportive treatment of heart failure caused by reduced myocardial contractility.Fosun Pharma's Hong Kong-listed shares rose 3%, while its Shanghai shares edged up 2% in early-morning trade on Monday.

HKG:2196SHA:600196
Asia

Fosun Pharmaceutical Gets Nod to Register Polyethylene Glycol and Electrolytes Powder

Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196), through unit Shanghai Fosun Pharmaceutical, obtained approval from China's National Medical Products Administration to register its Polyethylene Glycol (3350) and Electrolytes Powder, according to a Hong Kong bourse filing published late Monday.The drug is used for the treatment of faecal impacion in children from the age of 5 years.The pharmaceutical company invested 2.62 million yuan into the research and development of the drug.

HKG:2196SHA:600196
Asia

Fosun Pharma Units Get Registration Nod for Two Drugs in China

Two units of Shanghai Fosun Pharmaceutical's (HKG:2196) obtained drug registration approval for certain products from China's National Medical Products Administration, according to two Monday Hong Kong bourse filings.Suzhou Erye Pharmaceutical's Polyethylene Glycol and Electrolytes Powder got approved for the indications of the treatment of chronic constipation in children aged one to 11 and fecal impaction in children from the age of five years.Separately, Fosun Wanbang (Jiangsu) Pharmaceutical Group got a nod for Empagliflozin and Metformin Hydrochloride Sustained-release Tablets as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Clinical Trial Approval for Parkinson's Drug

Shanghai Fosun Pharmaceutical's (HKG:2196) subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical received approval from China's National Medical Products Administration to conduct a clinical trial of DM1001 Formulation for the treatment of signs and symptoms of Parkinson's disease, according to a Friday Hong Kong bourse filing.The company plans to commence a Phase I clinical trial in China once relevant conditions are met.

HKG:2196
Asia

Fosun Pharma Unit Gets China Clinical Trial Approval for Triglyceride Drug Candidate

Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) said subsidiary Fosun Pharmaceutical Industrial Development (Shenzhen) received China's National Medical Products Administration approval to conduct a clinical trial for FXR0906, a drug candidate for hypertriglyceridemia.Fosun Pharma (Shenzhen) plans to start a Phase I clinical trial in mainland China after fulfilling relevant conditions, according to Wednesday Hong Kong bourse filing.Shanghai Fosun Pharma's shares rose nearly 2% in recent trade.

HKG:2196SHA:600196
Asia

Junshi Biosciences Licenses Autoimmune Drug to Fosun Pharma

Shanghai Junshi Biosciences (HKG:1877, SHA:688180) agreed to license JS005 to Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) for the greater China region, according to a Wednesday filing with the Hong Kong bourse.The company will receive an upfront payment of 215 million yuan, plus a further 1.13 billion yuan in milestone-related payments.Junshi Biosciences will also receive royalty payments once the drug is commercialized in the greater China region.JS005, also known as roconkibart, is a treatment for autoimmune diseases such as psoriasis, rheumatoid arthritis and ankylosing spondylitis.

HKG:1877HKG:2196SHA:600196SHA:688180
Asia

Fosun Pharma to Offload Partnership Fund Stake for 1 Million Yuan; Shares Down 4%

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) and a subsidiary agreed to dispose of their stake in Jinan Fujian Partnership to Shanghai Fujian, according to a Shanghai bourse filing on Tuesday.Fosun will transfer its subscribed 7 million yuan interest in the partnership fund for 1.1 million yuan, while its subsidiary, Fosun Pingyao, will transfer its 1 million yuan stake for 150,000 yuan.After the transaction, the company will no longer own any equity in Jinan Fujian.The pharmaceutical company's Hong Kong shares dropped 4%, while Shanghai shares fell nearly 2% during the afternoon trade.

HKG:2196SHA:600196
Asia

Fosun Pharma's Unit Gets Registration Nod for Spasm, Pain Drug in China

Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) unit Hebei Wanbang Folon Pharmaceutical obtained approval for the registration application of Shaoyao Gancao Tang Granules from China's National Medical Products Administration.The drug is used for various spasm and pain conditions caused by insufficiency of yin and blood and malnourishment of the sinews and vessels that manifests as leg and feet spasms andabdominal pain, according to a Monday filing.

HKG:2196SHA:600196
Asia

Fosun Pharma's Vaccine Unit Submits Hong Kong Listing Application

Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) vaccine unit, Fosun Adgenvax, has submitted an application for a Hong Kong listing, according to a Friday Hong Kong bourse filing.The company plans to issue H-shares representing no more than 25% of its enlarged share capital, with an overallotment option of up to 15% of the initial offering size.Fosun Pharma said Fosun Adgenvax is expected to remain a subsidiary after the listing.

HKG:2196SHA:600196

Showing 1-20 of 32

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2196 in your portfolio
WheelAI
WheelAI
Analyze HKG:2196 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2196